Female Sexual Dysfunction: Treatment Options in 2026

Sexual health is part of whole-person health. When something interferes with it, the effects ripple outward: into relationships, self-image, mental health, and quality of life. Yet female sexual dysfunction (FSD) remains one of the most undertreated areas in medicine. Many women never bring it up with a provider. Many who do are dismissed or offered no real options.

That picture is changing. The treatment landscape for FSD has expanded considerably over the past decade, with FDA-approved medications, evidence-backed off-label options, and non-pharmacological approaches that genuinely help. If you or someone you care about is experiencing sexual difficulties, you deserve accurate, up-to-date information.

This article is an educational overview of what female sexual dysfunction is, what causes it, and what treatment options the research supports in 2026. It is not medical advice. Please consult a licensed healthcare provider to discuss your individual situation.

*This article is for educational purposes only. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any treatment.*

---

What Is Female Sexual Dysfunction?

Female sexual dysfunction is an umbrella term covering a range of persistent difficulties with sexual response that cause meaningful personal distress. The key word is distress. Low libido alone is not a disorder. It becomes clinically significant when it causes you real suffering or seriously affects your quality of life.

The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) organizes female sexual dysfunction into several categories. Understanding them matters because the treatments for each differ significantly.

Hypoactive Sexual Desire Disorder (HSDD)

Also referred to as Female Sexual Interest/Arousal Disorder (FSIAD) in DSM-5 terminology, HSDD is characterized by a persistent or recurrent absence of sexual thoughts, fantasies, and desire for sexual activity. When that absence causes significant personal distress, the diagnosis may apply.

HSDD is the most common form of FSD, affecting an estimated 8 to 15 percent of premenopausal women and a higher proportion of postmenopausal women. Research published in the *Journal of Sexual Medicine* suggests that meaningful distress about low desire affects roughly 10 percent of women in the United States at any given time.

Female Orgasmic Disorder (FOD)

Characterized by persistent difficulty reaching orgasm, reduced intensity of orgasm, or significant delay in orgasm despite adequate arousal. Like all FSD categories, it requires that the experience causes meaningful distress.

Genitopelvic Pain/Penetration Disorder (GPPPD)

This category covers difficulties related to vaginal penetration, including vaginismus (involuntary tightening of pelvic floor muscles) and dyspareunia (persistent genital pain during or after intercourse). It often has overlapping physical and psychological components.

Genitourinary Syndrome of Menopause (GSM)

Formerly called vulvovaginal atrophy, GSM is a term introduced in a 2014 consensus statement by the International Society for the Study of Women's Sexual Health and the North American Menopause Society (Portman and Gass, *Menopause*, 2014; PMID: 25160739). It describes the collection of symptoms that arise from declining estrogen levels: vaginal dryness, irritation, reduced lubrication, pain with intercourse, and urinary symptoms. GSM is not a minor inconvenience. It is a chronic, progressive condition that worsens without treatment.

---

What Causes Female Sexual Dysfunction?

FSD rarely has a single cause. In most cases, several factors interact.

Hormonal shifts are among the most common contributors. Perimenopause and menopause bring declining estrogen and testosterone levels. Estrogen supports vaginal tissue health, lubrication, and sensitivity. Testosterone plays a role in sexual desire and arousal in women, though the mechanisms are still being studied. Postpartum hormonal changes, oral contraceptives, and conditions like premature ovarian insufficiency can all affect sexual function.

Medical conditions that affect circulation, nerve function, or hormonal status, including cardiovascular disease, diabetes, multiple sclerosis, thyroid disorders, and cancer treatment, can contribute to FSD.

Medications are frequently overlooked contributors. Selective serotonin reuptake inhibitors (SSRIs), which are among the most commonly prescribed medications in the world, are associated with decreased libido, delayed orgasm, and anorgasmia in a significant proportion of users. Antihypertensives, antihistamines, and hormonal contraceptives can also affect sexual function.

Psychological factors including depression, anxiety, trauma history, and body image concerns have well-documented effects on sexual desire and response. These are not "just in your head," but they do require approaches that address the psychological dimension directly.

Relationship factors matter considerably. Unresolved conflict, mismatched desire levels, communication difficulties, and partner sexual dysfunction all affect sexual experience.

Lifestyle factors including chronic sleep deprivation, high stress, excessive alcohol use, and physical inactivity are associated with reduced sexual function.

---

*Hormonal shifts across the lifespan, including perimenopause and menopause, are among the most common contributors to changes in female sexual function.*

---

FDA-Approved Pharmacological Treatments

Flibanserin (Addyi): For Low Desire in Premenopausal Women

Flibanserin, sold under the brand name Addyi, was the first FDA-approved treatment for HSDD in premenopausal women. It received approval in 2015 after two rounds of review.

Flibanserin works through a different mechanism than most expect. It is not an aphrodisiac and it is not a hormonal therapy. It acts on serotonin and dopamine receptors in the brain, modulating neurotransmitter systems that affect sexual motivation. It is taken as a daily oral tablet at bedtime.

Clinical trials showed modest but statistically significant improvements in sexual desire and decreases in distress compared to placebo. The drug carries an important safety warning: it must not be combined with alcohol or with certain medications including fluconazole and other CYP3A4 inhibitors, as the combination can cause dangerously low blood pressure and fainting. It is not approved for postmenopausal women.

Providers approach flibanserin with varying levels of enthusiasm. Its modest effect size means it works meaningfully for some women but makes little difference for others.

Bremelanotide (Vyleesi): An On-Demand Option for HSDD

Bremelanotide, sold as Vyleesi, received FDA approval in 2019, also for HSDD in premenopausal women. Unlike flibanserin, it is taken on demand rather than daily: a subcutaneous injection administered approximately 45 minutes before anticipated sexual activity.

Bremelanotide works centrally, activating melanocortin receptors (specifically MC3R and MC4R) in areas of the brain involved in sexual motivation and reward. This central mechanism sets it apart from vascular approaches used for male sexual dysfunction.

The Phase 3 RECONNECT trials, which together enrolled more than 1,200 women, found that bremelanotide produced statistically significant improvements in sexual desire and reductions in distress related to low desire compared to placebo. A study published in *Obstetrics and Gynecology* (Kingsberg et al., 2019; PMID: 31599840) reported these findings across both trials.

Common side effects include nausea (in approximately 40 percent of users), flushing, and headache. It is contraindicated in people with cardiovascular disease or uncontrolled hypertension. Unlike flibanserin, there is no alcohol interaction restriction, though avoiding heavy alcohol use on days of administration is generally sensible.

For women who find daily medication impractical or who prefer an on-demand approach, bremelanotide offers a meaningfully different option. For a deeper look at the research, see the article on [PT-141 (bremelanotide) and the science behind it](/articles/pt-141-bremelanotide-sexual-health-research).

Ospemifene (Osphena): For Pain During Intercourse

Ospemifene is a selective estrogen receptor modulator (SERM) taken as a daily oral tablet. It is FDA-approved for moderate to severe dyspareunia (pain during intercourse) associated with vulvovaginal atrophy related to menopause.

Unlike vaginal estrogen, ospemifene is taken orally and acts on vaginal tissue without the systemic estrogen exposure that some women want to avoid. Clinical studies have shown improvements in vaginal dryness, pH, and pain scores compared to placebo.

Ospemifene carries a black box warning related to the endometrial effects common to estrogenic compounds, and is not appropriate for women with a history of estrogen receptor-positive breast cancer. A licensed provider can assess whether it is an appropriate option based on your medical history.

Prasterone (Intrarosa): Vaginal DHEA for Dyspareunia

Prasterone is a vaginal insert containing DHEA (dehydroepiandrosterone), a precursor hormone that the body converts locally into estrogen and androgen. It is FDA-approved for moderate to severe dyspareunia due to vulvovaginal atrophy of menopause.

Because it is applied locally, systemic hormone exposure is low, which makes it an option for some women who cannot or prefer not to use systemic estrogen therapy. Clinical trials have demonstrated improvements in vaginal dryness, lubrication, and pain scores.

Local Estrogen Therapy: First-Line for GSM

For women experiencing GSM, local (vaginal) estrogen therapy is generally considered the most effective and well-tolerated first-line pharmacological approach. Options include vaginal estrogen creams, rings (such as Estring), and low-dose tablets or inserts (such as Vagifem and Yuvafem).

Local estrogen restores vaginal tissue health by raising estrogen levels in the vaginal mucosa with minimal systemic absorption at the lowest approved doses. It is effective for dryness, reduced lubrication, dyspareunia, and urinary symptoms associated with GSM. For women with a history of estrogen receptor-positive breast cancer, use requires careful discussion with an oncologist and gynecologist.

---

Off-Label Treatments With Meaningful Evidence

Testosterone Therapy for Women

Testosterone is not FDA-approved for any indication in women in the United States, but its off-label use for female sexual dysfunction is supported by a substantial and growing body of evidence.

In 2019, an international consensus position statement from leading sexual health and endocrinology societies, including ISSWSH and IMSUT, concluded that testosterone therapy can improve sexual desire, arousal, orgasm, and related distress in postmenopausal women when used at physiological premenopausal concentrations (Davis SR et al., *Journal of Clinical Endocrinology and Metabolism*, 2019; PMID: 31498871). The evidence base for premenopausal women is less robust but growing.

Testosterone is typically prescribed as a [compounded medications](/resources/compounded-semaglutide-what-it-is) topical formulation at doses designed to bring serum testosterone into the physiological range for women. Compounded testosterone is not FDA-approved for any indication in women. Unlike FDA-approved medications, the quality, dosing accuracy, and batch-to-batch consistency of compounded preparations are not reviewed or verified by the FDA. Supraphysiological dosing carries risks including acne, hirsutism, voice changes, and potentially adverse cardiovascular effects. Regular lab monitoring is standard practice.

Providers experienced in women's hormonal health often include testosterone evaluation as part of a comprehensive workup for FSD, particularly in perimenopausal and postmenopausal women.

Bupropion: An Antidepressant With a Different Profile

For women whose FSD is partly or fully related to SSRI use, bupropion (Wellbutrin) is sometimes considered. Bupropion works through dopamine and norepinephrine pathways rather than serotonin, and has a significantly lower incidence of sexual side effects than SSRIs. In some cases, adding bupropion or switching to it can improve libido and orgasmic function for people experiencing SSRI-induced sexual dysfunction.

Bupropion is not an approved treatment for FSD and this represents an off-label use. It is also not appropriate for everyone, particularly people with a history of seizure disorders or eating disorders. This conversation requires a psychiatrist or prescribing provider who knows your full history.

---

*Non-pharmacological approaches, including pelvic floor physical therapy, mindfulness-based therapy, and sex therapy, are evidence-based components of comprehensive FSD treatment.*

---

Non-Pharmacological Approaches

Pelvic Floor Physical Therapy

For women with GPPPD, vaginismus, or dyspareunia with a musculoskeletal component, pelvic floor physical therapy (PFPT) is often among the most effective interventions available. A trained pelvic floor PT assesses the function of the muscles, connective tissue, and nerves of the pelvic region and uses techniques including manual therapy, biofeedback, and progressive desensitization to address dysfunction.

Many gynecologists and urogynecologists consider PFPT a cornerstone treatment for pelvic pain and penetration disorders, often recommending it before or alongside pharmacological options.

Sex Therapy and Cognitive Behavioral Therapy

FSD frequently has a meaningful psychological dimension, even when a clear physical cause exists. Sex therapy, provided by a licensed therapist with specialized training, addresses sexual beliefs, scripts, communication patterns, and anxiety that can perpetuate dysfunction even after underlying physical causes are treated.

Cognitive behavioral therapy (CBT) adapted for sexual dysfunction has a solid evidence base. It addresses thought patterns that interfere with sexual response, such as spectatoring (mentally observing yourself during sex rather than experiencing it), performance anxiety, and shame-based beliefs.

Sensate focus, a structured technique developed by Masters and Johnson and refined over decades, guides couples through non-demand physical exploration that rebuilds intimacy without pressure.

Mindfulness-Based Approaches

A growing body of research has examined mindfulness-based cognitive therapy (MBCT) adapted for women with sexual difficulties. This approach trains awareness of present-moment sensation without judgment, which directly addresses the cognitive distraction and self-monitoring that often interfere with arousal and orgasm. Studies have shown improvements in sexual desire, arousal, and satisfaction in women who complete mindfulness-based programs for sexual health.

Lubricants and Vaginal Moisturizers

For GSM-related dryness and pain, over-the-counter lubricants and vaginal moisturizers are practical first steps that provide meaningful relief for many women. They are not medical treatments, but they can significantly improve comfort during sexual activity. Water-based and silicone-based lubricants each have their applications. Vaginal moisturizers (such as Replens) are used regularly, not just at the time of intercourse, and help restore vaginal moisture over time.

---

How to Talk to Your Provider About FSD

Many women hesitate to bring up sexual concerns during medical appointments. If that resonates with you, here are a few things worth knowing.

You do not need to wait for your provider to ask. You can raise it directly. Something as simple as "I've noticed a significant change in my sex drive and it's affecting my quality of life" opens the door.

A thorough evaluation may include a review of your medical history and current medications (both are critical for identifying contributing factors), a pelvic exam, and targeted hormone testing including estrogen, testosterone, FSH, and thyroid function. A referral to a specialist, whether a gynecologist experienced in sexual medicine, a urologist, or an endocrinologist, may be appropriate depending on your situation.

Not every provider is equally comfortable or knowledgeable about FSD. If you feel dismissed, seeking a second opinion is entirely reasonable. Providers who specialize in sexual medicine and women's hormonal health tend to take a more systematic and evidence-informed approach.

---

Frequently Asked Questions

Is FSD the same as low libido? Low libido can be one component of FSD, specifically related to HSDD. But FSD is broader and includes difficulties with arousal, orgasm, and pain, each of which may have different causes and respond to different treatments.

Does FSD only affect older women? No. FSD occurs across all age groups. HSDD, for example, is most commonly diagnosed in premenopausal women. Younger women can experience orgasmic difficulties, GPPPD, and other forms of FSD for a range of reasons.

Are there treatments that work for postmenopausal women with low desire? The evidence for flibanserin and bremelanotide is specifically in premenopausal women. For postmenopausal women, testosterone therapy has the strongest evidence base for improving desire. Local estrogen or prasterone addresses GSM-related symptoms. A provider experienced in menopause management can help identify the right approach.

Can FSD be fully resolved? That depends heavily on the underlying cause and how long it has been present. When there is a clear, addressable cause, such as an SSRI-induced side effect or GSM, targeted treatment can produce significant or complete resolution. For more complex, multifactorial FSD, the goal is often meaningful improvement in function and reduction in distress rather than a complete "cure." Many women achieve that with the right combination of treatment approaches.

Is FSD a sign of relationship problems? Not necessarily. FSD can arise entirely from physiological causes with no relationship component. That said, relationship factors often contribute and are worth addressing alongside any medical treatment. Sex therapy can be valuable even in healthy relationships.

---

*This article is for educational and research purposes only. It does not constitute medical advice. Treatment decisions should be made in partnership with a licensed healthcare provider who has reviewed your complete medical history.*

*Addyi (flibanserin) and Vyleesi (bremelanotide) are FDA-approved for HSDD in premenopausal women. Osphena (ospemifene) and Intrarosa (prasterone) are FDA-approved for dyspareunia associated with menopause-related GSM. Compounded medications are not FDA-approved. Results may vary. Consult your healthcare provider.*

*This is not medical advice. All trademarks are the property of their respective owners. Prescriva is not affiliated with or endorsed by any pharmaceutical manufacturer.*

---

Sources

1. Portman DJ, Gass ML. Genitourinary Syndrome of Menopause: New Terminology for Vulvovaginal Atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. *Menopause.* 2014. [PMID: 25160739](https://pubmed.ncbi.nlm.nih.gov/25160739/)
2. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. *Obstetrics and Gynecology.* 2019. [PMID: 31599840](https://pubmed.ncbi.nlm.nih.gov/31599840/)
3. Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. *Journal of Clinical Endocrinology and Metabolism.* 2019. [PMID: 31498871](https://pubmed.ncbi.nlm.nih.gov/31498871/)
4. Goldstein I, et al. Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. *Mayo Clinic Proceedings.* 2017. [PMID: 27916394](https://pubmed.ncbi.nlm.nih.gov/27916394/)
5. Portman DJ, et al. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. *Menopause.* 2013. [PMID: 23361170](https://pubmed.ncbi.nlm.nih.gov/23361170/)

---

Talk to a Provider

Sexual health concerns are medical concerns. They deserve the same attention and care as any other aspect of your health. If you are experiencing changes in sexual desire, arousal, orgasm, or comfort that are affecting your quality of life, speaking with a licensed healthcare provider is the most important step you can take.

Prescriva connects you with providers who approach women's health comprehensively and take your concerns seriously.

*Consult your healthcare provider. Results may vary. This is not medical advice.*

[Connect With a Provider](#)